首页> 外文期刊>Cancer biology & therapy >T351 protein, a novel tumor associated antigen and potential target for immunotherapy.
【24h】

T351 protein, a novel tumor associated antigen and potential target for immunotherapy.

机译:T351蛋白是一种新型的肿瘤相关抗原,是免疫疗法的潜在靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

Tumor immunotherapy has attracted many attentions in recent years because of its high specificity. However, the use of immunotherapy is hampered by the lack of defined target tumor antigens. T351 gene, a novel tumor associated gene identified by mRNA differential display, encodes a transmembrane protein. We found that T351 is overexpressed in tumor tissues and tumor cell lines at both mRNA and protein levels by quantitative reverse transcription-PCR, immunohistochemistry and flow cytometry analyses, respectively. We also show that the extracellular portion of T351 protein termed T351pro.philic specifically activate CTLs to lyse tumor cell targets. In addition, a monoclonal antibody raised against T351pro.philic (McAb C1-1) induced murine macrophages to kill tumor cells effectively both in vitro and in vivo. These results suggest that T351 protein is a novel tumor associated antigen.
机译:近年来,肿瘤免疫疗法因其高特异性而备受关注。然而,缺乏确定的靶肿瘤抗原阻碍了免疫疗法的使用。 T351基因是一种通过mRNA差异显示技术鉴定的新型肿瘤相关基因,它编码一种跨膜蛋白。我们发现,分别通过定量逆转录PCR,免疫组织化学和流式细胞术分析,T351在mRNA和蛋白水平的肿瘤组织和肿瘤细胞系中均过表达。我们还显示,称为T351pro.philic的T351蛋白的胞外部分特异性激活CTL裂解肿瘤细胞靶标。另外,针对T351pro.philic(McAb C1-1)产生的单克隆抗体可诱导鼠巨噬细胞在体内外有效杀死肿瘤细胞。这些结果表明,T351蛋白是一种新型的肿瘤相关抗原。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号